Antifungal agents. Part I. Amphotericin B preparations and flucytosine

Mayo Clinic Proceedings

Volumn 73, Issue 12, 1998, Pages 1205-1225

  Patel, Robin ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CYCLOSPORIN; FLUCONAZOLE; FLUCYTOSINE; INTRALIPID; ITRACONAZOLE; KETOCONAZOLE;

CARDIOTOXICITY; CHILL; CONFERENCE PAPER; DOSE RESPONSE; DRUG FORMULATION; DRUG MECHANISM; DRUG MIXTURE; DRUG POTENTIATION; FEVER; FUNGAL MENINGITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION;

EID: 0031742198     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/73.12.1205     Document Type: Conference Paper

References (257)

1. Sarosi GA. Amphotericin B: still the 'gold standard' for antifungal therapy. Postgrad Med 1990 Jul;88:151-152; 155-161; 165-166
2. Gold W, Stout HA, Pagano JF, Donovick R. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. AntibiotAnn 1955-1956:3:579-586
3. Walsh TJ, Lyman CA. New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. Cancer Treat Res 1995;79:113-148
4. Hoeprich PO, Rynn NM, Kawachi MM, Lee KK, Lawrence RM, Heath LK, et al. Treatment of fungal infections with semisynthetic derivatives of amphotericin B alpha. Ann N Y Acad Sci 1988:544:517-546
5. Graybill JR. The future of antifungal therapy. Clin Infect Dis 1996;22(Suppl 2):S166-S178
6. Sokol-Anderson ML, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis 1986:154:76-83
7. Brajtburg J, Powderly WG, Kobayashl GS, Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 1990:34:183-188
8. Stiller RL, Bennett JE, Scholer HJ, Wall M, Polak A, Stevens DA. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother 1982:22:482-487
9. Shadomy S, Espinel-lngroff A, Cartwright RY. Laboratory studies with antifungal agents: susceptibility tests and bioassays. In: Lennette EH, Balows A, Hausler WJ Jr, Shadomy HJ, editors. Manual of Clinical Microbiology. 4th ed. Washington (DC): American Society for Microbiology; 1985. pp 991-999
10. McGinnis MR, Rinaldl MG. Antifungal drugs, in: Lorian V, editor. Antibiotics in Laboratory Medicine. 2nd ed. Baltimore: Williams & Wilkins; 1986
11. Oravcova E, Mlstrik M, Sakalova A, Drgona L, Hollar T, Helpianska L, et al. Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. Chemotherapy 1995;41:473-476
12. Speeleveld E, Cordts B, Van Landuyt HW, De Vroey C, Raes Wuytack C. Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses 1996:39:37-40
13. Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother 1991;28(Suppl B):27-38
14. Cross JT Jr, Hickerson SL, Yamauchi T. Antifungal drugs. Pediatr Rev 1995;16:123-129
15. Sterling TR, Gasser RA Jr, Ziegler A. Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Clin Infect Dis 1996:23:187-188
16. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologie stratégies. Antimicrob Agents Chemother 1996;40:279-291
17. Le TP, Tuazon CU, Le vine M, Borum M, Rollhauser C. Resistance to fluconazole and amphotericin B in a patient with AIDS who was being treated for candidal esophagitis. Clin Infect Dis 1996;23:649-650
18. Kelly SL, Lamb DC, Kelly DE, Manning NJ, Loeffler J, Hebart H, et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol deltas,6-desaturation. FEBS Lett 1997;400:80-82
19. Nolte FS, Parkinson T, Falconer DJ, Dix S, Williams J, Gilmore C, et al. Isolation and characterization of fluconazole- and amphotericin Bresistant Candida albicans horn blood of two patients with leukemia. Antimicrob Agents Chemother 1997;41:196-199
20. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996;34:489-495
21. Powderly WG, Keath EJ, Sokol-Anderson M, Robinson K, Kitz D, Little JR, et al. Amphotericin B-resistant Cryptococcus neoformans in a patient with AIDS. Infect Dis Clin Pract 1992;1:314-316
22. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B resistant yeast infection in severely immunocompromised patients. AmJMed 1988:84:826-832
23. Polak A. Pharmacokinetics of amphotericin B and flucytosine. Postgrad Med J 1979:55:667-670
24. Bindschadler DD, Bennett JE. A pharmacologie guide to the clinical use of amphotericin B. J Infect Dis 1969:120:427-436
25. Utz JP, Garriques IL, Sande MA, Warner JF, Mandell GL, McGehee RF, et al. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis 1975:132:368-373
26. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992:23:279-291
27. Atkinson AJ Jr, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978;13:271-276
28. Adamson PC, Rinaldi MG, Pizzo PA, Walsh TJ. Amphotericin B in the treatment of Candida cholecystitis. Pediatr Infect Dis J 1989;8:408411
29. Starke JR, Mason EO Jr, Kramer WG, Kaplan SL. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 1987:155:766-774
30. Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother 1989;33:1989-1993
31. Hoeprich PD. Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis 1992;14(Suppl 1):S114-S119
32. Hoeprich PD, Rinaldi MG. Candidosis. In: Hoeprich PD, Jordan MC, editors. Infectious Diseases. 4th ed. Philadelphia: Lippincott; 1989. pp 465-481
33. Schuler U, Ehninger G. Rapid infusion of amphotericin B: is it safe, effective, and wise? [letter]. Am J Med 1995:99:104-105
34. de Lalla F, Pellizzer G, Vaglia A, Manfrin V, Franzetti M, Fabris P, et al. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995;20:263-266
35. Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother 1985:27:868-871
36. Fields BT Jr, Bates JH, Abernathy RS. Effect of rapid intravenous infusion on serum concentrations of amphotericin B. Appl Microbiol 1971:22:615-17
37. Bowler WA, Weiss PJ, Hill HE, Hoffmeister KA, Fleck RP, Blacky AR, et al. Risk of ventricular dysrhythmias during 1-hour infusions of amphotericin B in patients with preserved renal function. Antimicrob Agents Chemother 1992;36:2542-2543
38. Oldfield EC III, Garst PD, Hostettler C, White M, Samuelson D. Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations. Antimicrob Agents Chemother 1990;34:14021406
39. Dele Davies H, King SM, Doyle J, Matlow A, Koren G, Hamilton R, et al. Controlled pilot study of rapid amphotericin B infusions. Arch Dis Child 1997:76:165-166
40. Nicholl TA, Nimmo CR, Shepherd JD, Phillips P, Jewesson PJ. Amphotericin B infusion-related toxicity: comparison of two- and fourhour infusions. Ann Pharmacother 1995:29:1081-1087
41. deary JD, Weisdorf D, Retcher CV. Effect of infusion rate on amphotericin B-associated febrile reactions. Drug Intell Clin Pharm 1988:22:769-772
42. 41a. Ellis ME, al-Hokail AA, Clink HM, Padmos MA, Ernst P, Spence DG, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother 1992:36:172-179
43. Gales MA, Gales BJ. Rapid infusion of amphotericin B in dextrose. Ann Pharmacother 1995:29:523-529
44. Chia JKS, McManus EJ. In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob Agents Chemother 1990:34:906908
45. Gigllotti F, Shenep JL, Lott L, Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J Infect Dis 1987:156:784789
46. Gelfand JA, Kimball K, Burke JF, Dinarello CA. Amphotericin B treatment of human mononuclear cells in vitro results in secretion of tumor necrosis factor and interleukin-1 [abstract]. Clin Res 1988;36:456A
47. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995;38:459-465
48. Tynes BS, Utz JP, Bennett JE, Ailing DW. Reducing amphotericin B reactions: a double-blind study. Am Rev Respir Dis 1963:87:264268
49. Burks LC, Aisner J, Fortner CL, Wiernik PH. Meperidine for the treatment of shaking chills and fever. Arch Intern Med 1980;140:483-484
50. Le Y, Rana KZ, Dudley MM. Amphotericin B-associated hypertension. Ann Pharmacother 1996;30:765-767
51. Barlows TG III, Luber AD, Jacobs RA, Guglielmo BJ. Hypothermia following the intravenous administration of amphotericin B. Clin Infect Dis 1996:23:1187-1188
52. Levy M, Domaratzki J, Koren G. Amphotericin-induced heart-rate decrease in children. Clin Pediatr (Phila) 1995;34:358-364
53. GrayblllJR. Systemic fungal infections: diagnosis and treatment. I. Therapeutic agents. Infect Dis Clin North Am 1988 Dec;2:805-825
54. Maddux MS, Barriere SL. A review of complications of amphotericinB therapy: recommendations for prevention and management. Drug Intell Clin Pharm 1980;14:177-181
55. Dana BW, Durie BG, White RF, Huestis DW. Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: absence of significant pulmonary toxicity. Blood 1981:57:90-94
56. Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981:304:1185-1189
57. Haber RH, Oddone EZ, Gurbel PA, Stead WW. Acute pulmonary decompensation due to amphotericin B in the absence of granulocyte transfusions [letter]. N EnglJ Med 1986:315:836
58. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf 1990:5:94-108
59. Wasan KM, Conklin JS. Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin Infect Dis 1997:24:78-80
60. Burgess JL, Birchall R. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am J Med 1972:53:7784
61. Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983;75:476-481
62. Branch RA. Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 1988:148:2389-2394
63. Sawaya BP, Weihprecht H, Campbell WR, Lorenz JN, Webb RC, Briggs JP, et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991:87:2097-2107
64. Wasan KM, Vadiei K, Lopez-Berestein G, Verani RR, Luke DR. Pentoxifylline in amphotericin B toxicity rat model. Antimicrob Agents Chemother 1990;34:241-244
65. Butler WT, Bennett JE, Ailing DW, Wertlake PT, Utz JP, Hill GJ II. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 1964:61:175-187
66. Feely J, Heidemann H, Gerkens J, Roberts U II, Branch RA. Sodium depletion enhances nephrotoxicity of amphotericin B [letter]. Lancet 1981:1:1422-1423
67. Ohnishi A, Ohnishi T, Stevenhead W, Robinson RD, Click A, O'Day DM, et al. Sodium status influences chronic amphotericin B nephrotoxicity in rats. Antimicrob Agents Chemother 1989:33:1222-1227
68. Branch RA, Jackson EK, Jacqz E, Stein R, Ray WA, Ohnhaus EE, et al. Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr 1987;65:500-506
69. Llanos A, Cleza J, Bernardo J, Echevarria J, Biaggioni I, Sabra R, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991:40:302-308
70. Anderson CM. Sodium chloride treatment of amphotericin B nephrotoxicity: standard of care? West J Med 1995:162:313-317
71. Bullock WE, Luke RG, Nuttall CE, Bhathena D. Can mannitol reduce ampnotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys. Antimicrob Agents Chemother 1976;10:555-563
72. Butler WT. Pharmacology, toxicity, and therapeutic usefulness of amphotericin B. JAMA 1966;195:371-375
73. Warda J, Barriere SL. Amphotericin B nephrotoxicity. Drug Intell Clin Pharm 1985;19:25-26
74. Barton CH, Pahl M, Vaziri ND, Cesario T. Renal magnesium wasting associated with amphotericin B therapy. Am J Med 1984:77:471474
75. Lin AC, Goldwasser E, Bernard EM, Chapman SW. Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 1990:161:348-51
76. MacGregor RR, Bennett JE, Erslev AJ. Erythropoietin concentration in amphotericin B-induced anemia. Antimicrob Agents Chemother 1978;14:270-273
77. Li PK, Lai KN. Amphotericin B induced ocular toxicity in cryptococcal meningitis. Br J Ophthalmol 1989;73:397-398
78. Devuyst 0, Coffin E, van Ypersele de Strihou C. Recurrent hemiparesis under amphotericin B for Candida albicans peritonitis. Nephrol Dial Transplant 1995;10:699-701
79. Liu JS, Chang YY, Chen WH, Chen SS. Amphotericin B-induced leukoencephalopathy in a patient with cryptococcal meningitis. J Formos Med Assoc 1995;94:432-434
80. Carnevale NT, Galgiani JN, Stevens DA, Herrlck MK, Längsten JW. Amphotericin B-induced myelopathy. Arch Intern Med 1980; 140:1189-1192
81. Dean JL, Wolf JE, Ranzini AC, Laughlln MA. Use of amphotericin B during pregnancy: case report and review. Clin Infect Dis 1994;18:364-368
82. Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983:35:211-215
83. Bianco JA, Almgren J, Kern DL, Ballard B, Roark K, Andrews F, et al. Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine: results of a pilot study. Transplantation 1991;51:925-927
84. Antoniskis D, Larsen RA. Acute, rapidly progressive renal failure with simultaneous use of amphotericin B and pentamidine. Antimicrob Agents Chemother 1990:34:470-472
85. Kulkantrakorn K, Selhorst JB, Petruska PJ. Cytosine arabinoside and amphotericin B-induced parkinsonism [letter]. Ann Neurol 1996:39:413-414
86. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995:39:1907-1912
87. Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 1985; 151:902-910
88. Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy 1987:33:381-395
89. George D, Kordick D, Miniter P, Patterson TF, Andriole VT. Combination therapy in experimental invasive aspergillosis. J Infect Dis 1993:168:692-698
90. Lecciones JA, Lee JW, Navarro EE, Witebsky FG, Marshall D, Steinberg SM, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992:14:875-883
91. Edwards JE Jr, Bodey GP, Bowden RA, Büchner T, de Pauw BE, Filler SG, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997:25:43-59
92. Phillips P, Shafran S, Garber G, Rotsteln C, Smaill F, Fong I, et al (Canadian Candidemia Study Group). Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 1997:16:337-345
93. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun 0, Pinczowski H, Kontoyiannis DP, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-176
94. Driessen M, Ellis JB, Cooper PA, Wainer S, Muwazi F, Hahn D, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 1996:15:1107-1112
95. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al (Candidemia Study Group and the National Institute). A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-1330
96. Anaissie EJ, Daroulche RO, Abl-Said D, Uzun 0, Mera J, Gentry LO, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23:964-972
97. Kujath P, Lerch K, Kochendorfer P, Boos C. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993;21:376382
98. Abele-Horn M, Kopp A, Sternberg U, Ohly A, Dauber A, Russwurm W, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996;24:426-432
99. Thaler M, Pastakla B, Shawker TH, O'Leary T, Plzzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988;108:88-100
100. Lai ST, Yeung YM. Ultra-long amphotericin B therapy for hepatosplenic candidiasis complicating acute promyelocytic leukaemia [letter]. Clin Lab Haematol 1996;18:62-63
101. Sobel JD, Vazquez J. Candidemia and systemic candidiasis. Semin Respir Infect 1990;5:123-137
102. Peterson LR, Kelty RH, Hall WH, Votava HJ. Therapy of Candida peritonitis: penetration of amphotericin B into peritoneal fluid. Postgrad Med J 1978:54:340-342
103. Bayer AS, Blumenkrantz MJ, Montgomerie JZ, Galpin JE, Coburn JW, Guze LB. Candida peritonitis: report of 22 cases and review of the English literature. Am J Med 1976;61:832-840
104. Struijk DG, Krediet RT, Boeschoten EW, Rletra PJ, Arisz L Antifun gal treatment of Candida peritonitis in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1987;9:66-70
105. Eisenberg ES, Leviton I, Soeiro R. Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature. Rev Infect Dis 1986;8:309-321
106. Fisher JF, Newman CL, Sobel JD. Yeast in the urine: solutions for a budding problem. Clin Infect Dis 1995;20:183-189
107. Rsher JF, Hicks BC, Diplro JT, Venable J, Fincher R-ME. Efficacy of a single intravenous dose of amphotericin B in urinary tract infections caused by Candida. J Infect Dis 1987;156:685-687
108. Wise GJ, Kozinn PJ, Goldberg P. Amphotericin B as a urologie irrigant in the management of noninvasive candiduria. J Urol 1982; 128:82-84
109. Trinh T, Simonian J, Vigil S, Chin D, Bidair M. Continuous versus intermittent bladder irrigation of amphotericin B for the treatment of candiduria. J Urol 1995;154:2032-2034
110. Jacobs LG, Skidmore EA, Freeman K, Lipschultz D, Fox N. Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients. Clin Infect Dis 1996;22:30-35
111. Leu HS, Huang CT. Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study. Clin Infect Dis 1995;20:1152-1157
112. Fan-Havard P, O'Donovan C, Smith SM, Oh J, Bamberger M, Eng RH. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis 1995;21:960965
113. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N EnglJ Med 1979:301:126-131
114. Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Craven PC, et al (National Institute of Allergy and Infectious Diseases Mycoses Study Group). Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N EnglJ Med 1987;317:334-341
115. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990:113:183-187
116. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al (NIAID Mycoses Study Group and AIDS Clinical Trials Group). Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl JMed 1992:326:83-89
117. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Grayblll JR, Sobel JD, et al (National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group). Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997:337:15-21
118. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, et al (NIAID AIDS Clinical Trials Group and NIAID Mycoses Study Group). A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-798
119. Polak A. Combination therapy for systemic mycosis. Infection 1989:17:203-209
120. Burch PA, Karp JE, Merz WG, Kuhlman JE, Rshman EK. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987;5:1985-1993
121. Karp JE, Burch PA, Merz WG. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 1988:85:203-206
122. Ryan PJ, Stableforth DE, Reynolds J, Muhdi KM. Treatment of pulmonary aspergilloma in cystic fibrosis by percutaneous instillation of amphotericin B via indwelling catheter. Thorax 1995:50:809810
123. Parker JD, Doto IL, Tosh FE. A decade of experience with blastomycosis and its treatment with amphotericin B: a National Communicable Disease Center Cooperative Mycoses Study. Am Rev Respir Dis 1969;99:895-902
124. Sathapatayavongs B, Batteiger BE, Wheat J, Slama TG, Wass JL. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine 1983;62:263-270
125. McKinsey DS, Gupta MR, Riddler SA, Driks MR, Smith DL, Kurtin PJ. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989:111:655-659
126. Ampel NM, Wieden MA, Galgiani JN. Coccidioidomycosis: clinical update. Rev Infect Dis 1989:11:897-911
127. Yudell A, Hendin BA, Tamm HS, Guidry J. Coccidioidal meningitis narcotic-amphotericin B intracisternal therapy [letter]. Arch Intern Med 1988:148:985
128. Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment and outcome. Medicine 1986;65:143-153
129. Bibler MR, Luber HJ, Glueck HI, Estes SA. Disseminated sporotrichosis in a patient with HIV infection after treatment for acquired factor VIII inhibitor. JAMA 1986:256:3125-3126
130. RestrepoA. Paracoccidioides brasiliensis. In: Mandell GL, Douglas RG Jr, Bennett JE, editors. Principles and Practice of Infectious Diseases. 3rd ed. New York: Churchill Livingstone; 1990. pp 2028-2031
131. Duong TA. Infection due to Pénicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996:23:125-130
132. Sugar AM. Agents of mucormycosis and related species. In: Mandell GL, Douglas RG Jr, Bennett JE, editors. Principles and Practice of Infectious Diseases. 3rd ed. New York: Churchill Livingstone; 1990. pp 1962-1972
133. Blazquez R, Pinedo A, Cosin J, Miralles P, Lacruz C, Bouza E. Nonsurgical cure of isolated cerebral mucormycosis in an intravenous drug user. Eur J Clin Microbiol Infect Dis 1996:15:598-599
134. McCormack JG. Intrathecal amphotericin B therapy for cerebral mucormycosis [letter]. Clin Infect Dis 1995:21:1352
135. Luna JD, Ponssa XS, Rodriguez SD, Luna NC, Juarez CP. Intraconal amphotericin B for the treatment of rhino-orbital mucormycosis. Ophthalmic Surg Lasers 1996:27:706-708
136. Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine 1986:65:268-279
137. Richardson SE, Bannatyne RM, Summerbell RC, Milliken J, Gold R, Weitzman SS. Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis 1988:10:1171-1181
138. Velasco E, Martins ÇA, Nucci M. Successful treatment of catheterrelated fusarial infection in immunocompromised children. EurJ Clin Microbiol Infect Dis 1995:14:697-699
139. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-111
140. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989:86:668-672
141. Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCredie KB. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother 1987;31:11-15
142. Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. EurJ Cancer 1996;32A:814-820
143. Ellis ME, Halim MA, Spence D, Ernst P, Clink H, Kalin M, et al. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever-preliminary observations from a pilot, exploratory study. J Infect 1995;30:141-146
144. Blumberg EA, Reboli AC. Failure of systemic empirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer. Clin Infect Dis 1996:22:462-466
145. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992:165:891-897
146. Riley DK, Pavia AT, Beatty PG, Petersen FB, Spruance JL, Stokes R, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994:97:509-514
147. Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990:5:403-406
148. Jeffery GM, Beard ME, Ikram RB, Chua J, Alien JR, Heaton DC, et al. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991;90:685-692
149. Dubois J, Bartter T, Gryn J, Pratter MR. The physiologic effects of inhaled amphotericin B. Chest 1995;108:750-753
150. Reichenspurner H, Gamberg P, Nitschke M, Valantine H, Hunt S, Oyer PE, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997:29:627-628
151. Jorgensen CJ, Dreyfus F, Vaixeler J, Guyomard S, Massiot C, Belanger C, et al. Failure of amphotericin B spray to prevent aspergillosis in granulocytopenic patients. Nouv Rev Fr Hematol 1989'31'327-328
152. Behre GF, Schwarte S, Lenz K, Ludwig WD, Wandt H, Schilling E, et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995:71:287-291
153. Roth C, Gebhart J, Just-Nubling G, von Eisenhart-Rothe B, Beinhauer-Reeb I. Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis. Infection 1996:24:354-360
154. Tsourounis C, Guglielmo BJ. Aerosolized amphotericin B in prophylaxis of pulmonary aspergillosis. Ann Pharmacother 1996:30:11751176
155. Hartsel S, Bolard J. Amphotericin B: new life for an old drug. Trends Pharmacol Sci 1996;17:445-449
156. Wasan KM, Lopez-Berestein G. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin Infect Dis 1996:23:1126-1138
157. Graybill JR. Lipid formulations for amphotericin B: does the emperor need new clothes? [editorial]. Ann Intern Med 1996:124:921923
158. Wong-Beringer A. Criteria for use of amphotericin B lipid complex injection in adults and children. Am J Health Syst Pharm 1996:53:2751-2752
159. Kan VL, Bennett JE, Amantea MA, Smolskis MC, McManus E, Grasela DM, et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis 1991:164:418-421
160. Adedoyin A, Bernardo JF, Swenson CE, Bolsack LE, Horwith G, DeWit S, et al. Pharmacokinetic profile of Abelcet (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother 1997;41:22012208
161. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991:35:615-621
162. Kline S, Larsen TA, Fieber L, Fishbach R, Greenwood M, Harris R, et al. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infect Dis 1995;21:11541158
163. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-321
164. Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1994;34:247
165. Anaissie EJ, White M, Uzun 0, Singer C, Bodey GP, Matzke D, et al. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1995:35:330
166. Mehta J, Kelsey S, Chu P, Powles R, Hazel D, Riley U, et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hématologie malignancies. Bone Marrow Transplant 1997;20:3943
167. Wlngard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997;19:343-347
168. Strasser MD, Kennedy RJ, Adam RD. Rhinocerebral mucormycosis: therapy with amphotericin B lipid complex. Arch Intern Med 1996:156:337-339
169. Wolff MA, Ramphal R. Use of amphotericin B lipid complex for treatment of disseminated cutaneous Fusarium infection in a neutropenic patient [letter]. Clin Infect Dis 1995:20:1568-1569
170. Patterson TS, Barton LL, Shehab ZM, Mutter JJ. Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium so/an/ infection. Clin Pediatr (Phila) 1996;35:257-260
171. Hospenthal DR, Byrd JC, Welss RB. Successful treatment of invasive aspergillosis complicating prolonged treatment-related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex. Med Pediatr Oncol 1995;25:119-122
172. Walsh TJ, Whltcomb P, Plscitelll S, Figg WD, Hill S, Chanock SJ, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997;41:1944-1948
173. Arney KL, Tlernan R, Judson MA. Primary pulmonary involvement of Fusarium solani in a lung transplant recipient. Chest 1997:112:1128-1130
174. Gonzalez CE, Courlel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997;24:192-196
175. Hanson LH, Stevens DA. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents Chemother 1992:36:486-488
176. Leenders AC, de Marie S. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996:10:1570-1575
177. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996:173:1208-1215
178. Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD. Population pharmacokinetics and renal functionsparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother 1995:39:2042-2047
179. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995:21:1145-1153
180. White MH, Bowden RA, Sandier E, Graham ML, Noskin G, Wlngard JR, et al. Amphotericin B colloidal dispersion (ABCD) vs. amphotericin B (AmB) in the empiric treatment of febrile neutropenic patients [abstract]. Blood 1996;88(Suppl l):302a
181. White MH, Analssie EJ, Kusne S, Wlngard JR, Hiemenz JW, Cantor A, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997;24:635642
182. Herbrecht R. Safety of amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 1997:16:74-80
183. Sanders SW, Buch! KN, Goddard MS, Lang JK, Tolman KG. Singledose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother 1991:35:1029-1034
184. Beovlc B, Lejko-Zupanc T, Pretnar J. Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 1997:16:507511
185. Valero G, Graybill JR. Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Antimicrob Agents Chemother 1995:39:2588-2590
186. Helnemann V, Kahny B, Debus A, Wachholz K, Jehn U. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipidbased formulations. Bone Marrow Transplant 1994;14(Suppl 5VS8-S9
187. Heinemann V, Bosse D, Jehn U, Kahny B, Wachholz K, Debus A, et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob Agents Chemother 1997:41:12751280
188. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 1995:155:1093-1098
189. Meunier F, Prentice HG, Ringden 0. Liposomal amphotericin B (AmBisome): safety data from a phase ll/lll clinical trial. J Antimicrob Chemother 1991;28(Suppl B):83-91
190. Heinemann V, Bosse D, Jehn U, Debus A, Wachholz K, Forst H, et al. Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure. JAntimicrob Chemother 1997;40:295-297
191. Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey GP. Comparison of the in vitro antifungal activity of free and liposomeencapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 1991;10:665-668
192. Shaunak S, Cohen J. Lack of toxicity of long-term, high total dose liposomal amphotericin B [letter]. J Antimicrob Chemother 1994:34:451-452
193. Berenguer J, Munoz P, Parras F, Fernandez-Baca V, HernandezSampelayo T, Bouza E. Treatment of deep mycoses with liposomal amphotericin B. Eur J Clin Microbiol Infect Dis 1994;13:504-507
194. Krüger W, Stockschläder M, Rüssmann B, Berger C, Hoffknecht M, Sobottka l, et al. Experience with liposomal amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation. Br J Haematol 1995;91:684690
195. Chopra R, Blair S, Strang J, Cervi P, Patterson KG, Goldstone AH. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother 1991;28(Suppl B):93-104
196. Chopra R, Fielding A, Goldstone AH. Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome)-a report on 40 cases from a single centre. Leuk Lymphoma 1992;7(Suppl):73-77
197. Goldstone AH, O'Driscoll A. Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant 1994;14(Suppl 5):S15-S17
198. Ringden 0, Andstrom E, Remberger M, Svahn BM, Tollemar J. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 1994;14(Suppl 5):S10-S14
199. Ringden 0, Tollemar J. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children. Mycoses 1993:36:187-192
200. Andstrom EE, Ringden 0, Remberger M, Svahn BM, Tollemar J. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycoses 1996;39:185-193
201. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. BrJ Haematol 1994:86:754-760
202. Tollemar J, Andersson S, Ringden 0, Tyden G. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients. Mycoses 1992;35:215-220
203. Ringden 0, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28(Suppl B):73-82
204. Paslc S, Flannagan L, Cant AJ. Liposomal amphotericin (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency. Bone Marrow Transplant 1997;19:1229-1232
205. Ralph ED, Barber KR, Grant CW. Clinical experience with multilamellar liposomal amphotericin B in patients with proven and suspected fungal infections. Scand J Infect Dis 1993:25:487-496
206. Arning M, Heer-Sonderhoff AH, Wehmeler A, Schneider W. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur J Clin Microbiol Infect Dis 1994:14:41-43
207. Ringden 0, Andstrom E, Remberger M, Svahn BM, Tollemar J. Allergic reactions and other rare side-effects of liposomal amphotericin [letter]. Lancet 1994;344:1156-1157
208. Bates CM, Carey PB, Hind CR. Anaphylaxis due to liposomal amphotericin [letter]. Genitourin Med 1995;71:414
209. Lalng RB, Milne U, Leen CL, Malcolm GP, Steers AJ. Anaphylactic reactions to liposomal amphotericin [letter]. Lancet 1994;344:682
210. Aguado JM, Hidalgo M, Moya I, Alcazar JM, Jlmenez MJ, Noriega AR. Ventricular arrhythmias with conventional and liposomal amphotericin [letter]. Lancet 1993:342:1239
211. Prentice HG, Kann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. BrJ Haematol 1997:98:711-718
212. Walsh T, Bodensteiner D, Hiemenz J, Thaler S, Greenberg R, Arndt C, et al. A randomized, double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1997:37:381
213. Kruger W, Stockschläder M, Sobottka I, Betker R, De Wit M, Kroger N, et al. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation. Leuk Lymphoma 1997;24:491-499
214. Bohme A, Hoelzer D. Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients. Mycoses 1996;39:419-426
215. Coker RJ, Vivian! M, Gazzard BG, Du Pont B, Pohle HD, Murphy SM, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993;7:829835
216. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11:1463-1471
217. Harten P, Baron Y, Euler HH. Liposomal amphotericin B therapy in disseminated histoplasmosis [letter]. Arch Intern Med 1995; 155:1556
218. Jantunen E, Kolho E, Ruutu P, Koukila-Kahkola P, Virolainen M, Juvonen E, et al. Invasive cutaneous mucormycosis caused by Absidia corymbifera after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;18:229-230
219. Ellis ME, Clink H, Younge D, Hainau B. Successful combined surgical and medical treatment of Fusarium infection after bone marrow transplantation. Scand J Infect Dis 1994;26:225-228
220. Sharland M, Hay RJ, Davies EG. Liposomal amphotericin B in hepatic candidosis. Arch Dis Child 1994;70:546-547
221. Sivakumaran M, Swann RA, Mitchell VE, Qureshi H, Wood JK. Therapeutic efficacy of AmBisome: a cautionary note [letter]. Am J Hematol 1995;48:208-209
222. Tollemar J, Ringden 0, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12:577-582
223. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden 0. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: a randomized, placebo-controlled study. Transplantation 1995;59:45-50
224. Persson U, Tennvall GR, Andersson S, Tyden G, Wettermark B. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconomics 1992;2:500-508
225. Sievers TM, Kubak BM, Wong-Beringer A. Safety and efficacy of Intralipid emulsions of amphotericin B. J Antimicrob Chemother 1996;38:333-347
226. Trissel LA. Amphotericin B does not mix with fat emulsion [letter]. Am J Health Syst Pharm 1995;52:1463-1464
227. Sacks GS, Cleary JD. Nutritional impact of lipid-associated amphotericin B formulations [letter]. Ann Pharmacother 1997; 31:121-122
228. Swenson CE, Bolcsak LE, Perkins WR, Janoff AS. Lipid-based formulations of amphotericin B [letter]. J Antimicrob Chemother 1995:35:709-713
229. Diasio RB, Bennett JE, Myers CE. Mode of action of 5fluorocytosine. Biochem Pharmacol 1978:27:703-707
230. Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 1975:21:113-130
231. Medoff G, Comfort M, Kobayashi GS. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med 1971:138:571-574
232. Beggs WH, Andrews FA, Sarosi GA. Combined action of amphotericin B and 5-fluorocytosine on pathogenic yeasts susceptible to either drug alone. Chemotherapy 1981;27:247-251
233. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992;15:10031018
234. Schönebeck J, Polak A, Fernex M, Scholer HJ. Pharmacokinetics studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy 1973:18:321-336
235. Gillum JG, Johnson M, Lavoie S, Venitz J. Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection. Pharmacotherapy 1995;15:251-253
236. BennettJE. Flucytosine. Ann Intern Med 1977:86:319-322
237. Bennett JE. Antifungal agents. In: Gilman AG, Rail TW, Nies AS, Taylor P, editors. Goodman and Oilman's The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press; 1990. pp 1165-1181
238. Lau AH, Kronfol NO. Elimination of flucytosine by continuous hemofiltration. Am J Nephrol 1995;15:327-331
239. Supparatpinyo K, Nelson KE, Merz WG, Breslin BJ, Cooper CR Jr, Kamwan C, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Pénicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993:37:24072411
240. Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles ÇA, et al (National Institute of Allergy and Infectious Diseases Mycoses Study Group). Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987:83:236-242
241. Harris BE, Manning BW, Federle TW, Diasio RB. Conversion of 5fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother 1986:29:44-48
242. Terrell CL, Hermans PE. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc 1987;62:1116-1128
243. Allendoerfer R, Marquis AJ, Rinaldi MG, Graybill JR. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother 1991;35:726-729
244. Kartalija M, Kaye K, Tureen JH, Liu Q, Tauber MG, Elliott BR, et al. Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologie and pathophysiologic outcome. J Infect Dis 1996;173:1216-1221
245. Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994:19:741-745
246. Polak A. Combination therapy with antifungal drugs. Mycoses 1988:31:45-53
247. Martin E, Maier F, Bhakdi S. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother 1994;38:1331-1338
248. Smego RA Jr, Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984;6:791-801
249. Wise GJ, Kozinn PJ, Goldberg P. Flucytosine in the management of genitourinary candidiasis: 5 years of experience. J Urol 1980:124:70-72
250. Dreetz DJ, Fetchick R. Fungal infections of the kidney and urinary tract. In: Schrier RW, Gottschalk CW, editors. Diseases of the Kidney. Vol 1. 4th ed. Boston: Little, Brown; 1988. pp 10151047
251. Mary C, Goudard M, Blancard A, Quilici M, Regli P. Effet synergique entre la 5-fluorocytosine et les dérivés imidazolés vis-à-vis de souches de levures résistantes àla 5-fluorocytosine. Ann Biol Clin (Paris) 1989;47:546-549
252. Barbara G, Barbarini G, Di Lorenzo G (Candida Esophagitis Multicenter Italian Study [CEMIS] Group). Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients: a double-blind, multicenter placebocontrolled study. Chest 1996:110:1507-1514
253. Barbara G, Di Lorenzo G. Comparison of therapeutic activity of fluconazole and itraconazole in the treatment of oesophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. ItalJ Gastroenterol 1995;27:175-180
254. Barbara G, Barbarini G, Di Lorenzo G. Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a doubleblind, placebo-controlled study. Endoscopy 1995:27:377-383
255. Vandevelde AG, Mauceri AA, Johnson JE III. 5-Fluorocytosine in the treatment of mycotic infections. Ann Intern Med 1972:77:43-51
256. Lopes CF, Alvarenga RJ, Cisalpino EO, Resende MA, Oliveira LG. Six years' experience in treatment of chromomycosis with 5fluorocytosine. IntJDermatol 1978:17:414-418
257. Ferreira Lopes C. Recent developments in the therapy of chromoblastomycosis. Bull Pan Am Health Organ 1981:15:58-64